Is CinCor Pharma, Inc. (CINC) a Buy, Sell, or Hold?
NASDAQ : CINC
CinCor Pharma, Inc.
$29.06 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 619.3K
- Market Capitalization
- $1.27B
- P/E Ratio
- -20.46
- Dividend Yield
- 0.00%
- Price Target
- $45.50
- Year High
- $43.15
- Year Low
- $10.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.53
Company Overview
NASDAQ
Marc M. P. de Garidel
Biotechnology
Healthcare
CINC
19
US
USD
Liquidity Metrics
0.00
8.53
8.53
8.25
0.00
Sales & Valuation
-$
0.00
-16.15
-41.23
-0.87
Profitability
-$1.42
-$50.35M
0.00%
0.00%
110.68%
-35.68%
P/E Metrics
-20.46
0.23
0.23
Analyst Price Target & Rating
$45.50
$73.00
$30.00
0/5
7 Analysts
-36.13%
Financial Health Scores
75.22
2/9
$518.84M
$529.12M
$10.18M
-$87.23M
Key Metrics (TTM)
$1.14B
0.00
-32.78
8.53
110.68%
-34.11%
-4.89%
-2.43%
0 days
Company Executives
| Name | Title |
|---|---|
| Hema Keshava | Corporation Controller |
| Ida Hatoum | Senior Vice President and Head of People, Talent & Culture |
| Michael W. Kalb | Executive Vice President, Chief Financial Officer & Principal Accounting Officer |
| Mason W. Freeman | Chief Medical Officer |
| Marc de Garidel | Chief Executive Officer & Director |
| Catherine Pearce DHSc | Co-Founder & Chief Operating Officer |
Poll Results
No votes yet today — be the first to share your view!
About CinCor Pharma, Inc. (NASDAQ:CINC) Stock
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts. ...
Frequently Asked Questions
-
What is the current CinCor Pharma, Inc. (CINC) stock price?
-
CinCor Pharma, Inc.(NASDAQ:CINC) stock price is $29.06 in the last trading session. During the trading session, CINC stock reached the peak price of $43.15 while $10.53 was the lowest point it dropped to. The percentage change in CINC stock occurred in the recent session was 0.0% while the dollar amount for the price change in CINC stock was $0.
-
CINC's industry and sector of operation?
-
The NASDAQ listed CINC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CINC?
-
Hema Keshava | Corporation Controller
Ida Hatoum | Senior Vice President and Head of People, Talent & Culture
Michael W. Kalb | Executive Vice President, Chief Financial Officer & Principal Accounting Officer
Mason W. Freeman | Chief Medical Officer
Marc de Garidel | Chief Executive Officer & Director -
How many employees does CINC have?
-
Number of CINC employees currently stands at 19. CINC operates from 200 Clarendon Street, Boston, MA 02116, US.
-
Link for CINC official website?
-
Official Website of CINC is: https://parkedpage.astrazeneca.com
-
How do I contact CINC?
-
CINC could be contacted at phone #844 531 1834 and can also be accessed through its website. CINC operates from 200 Clarendon Street, Boston, MA 02116, US.
-
How many shares of CINC are traded daily?
-
The average number of CINC shares traded daily for last 3 months was 619.3K.
-
What is the market cap of CINC currently?
-
The market value of CINC currently stands at $1.27B with its latest stock price at $29.06